Equities

Tron Pharmaceuticals Inc

TGRP:PKC

Tron Pharmaceuticals Inc

Actions
  • Price (USD)0.1275
  • Today's Change-0.052 / -29.16%
  • Shares traded475.64k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Sep 19 2024 20:55 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Tron Pharmaceuticals, Inc. formerly Nanopharmaceutics, Inc., is a clinical-stage specialty pharmaceutical company. The Company is developing oral, topical, and injectable products for cancer, central nervous system (CNS) disorders, and infectious diseases. It is developing a clinical pipeline of oral, topical and injectable small molecule drug candidates to treat human cancer, central nervous system (CNS) disorders and infectious diseases. Its pipeline includes 10 clinical-stage proprietary and partnered programs including Triapine, Ammonium Tetrathiomolybdate and Aza-TdC, targeting cancer; NanoBUP, PRX-3140, NP-18-2, and NP-18-3, targeting CNS; and Ramoplanin and NanoDOX, targeting infectious disease. Leveraging its expertise in nanoparticle and fine-particle formulations, the Company is focused on formulation development aimed at improving drug absorption and stability. Its Triapine is a synthetic heterocyclic carboxaldehyde thiosemicarbazone with potential antineoplastic activity.

  • Revenue in USD (TTM)1.01m
  • Net income in USD-549.47k
  • Incorporated2015
  • Employees50.00
  • Location
    Tron Pharmaceuticals IncK-2-8 2nd. Floor Kuchai Business ParkJalan 1/127 Off Jalan Kuchai LamaKUALA LUMPUR 58200MalaysiaMYS
  • Phone+60 379878688
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
TGRP:PKC since
announced
Transaction
value
Himepla IncAnnounced31 Jan 202431 Jan 2024Announced-79.11%--
Data delayed at least 15 minutes, as of Sep 19 2024 20:55 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Palatin Technologies, Inc.5.90m-32.20m20.82m34.00--13.18--3.53-2.39-2.390.42750.09790.31890.64026.95173,588.80-173.98-26.11-387.23-30.6896.58---545.58-126.201.20--0.0443--230.53-40.8723.91--80.82--
MEI Pharma Inc66.75m26.16m20.92m46.000.79990.410.78920.31343.933.9310.027.660.6498--29.151,451,174.0025.46-25.3130.38-28.59----39.18-122.05----0.00--19.9597.5641.53------
Pieris Pharmaceuticals Inc20.87m-23.82m22.43m46.00--1.20--1.07-19.12-19.1216.6714.170.3707--17.13453,739.10-42.31-28.41-66.27-39.69-----114.11-94.61----0.00--65.288.0326.25---36.82--
Geovax Labs Inc300.68k-26.92m22.64m17.00------75.31-13.05-13.050.1389-0.55260.0237----17,687.06-212.40-108.34-362.39-147.24-----8,951.51-1,842.93---------100.00---85.20------
Tron Pharmaceuticals Inc1.01m-549.47k23.45m50.00------23.23-0.0034-0.00340.0062-0.0508------20,191.00--------60.28---110.51--0.0417-433.32----0.3272---39.70------
RenovoRx Inc0.00-8.11m23.60m8.00--2.54-----0.6059-0.60590.000.38680.00----0.00-88.58---106.00--------------0.00-------3.47------
Biora Therapeutics Inc860.00k-86.81m23.70m58.00------27.56-5.57-5.560.024-2.490.0253--1.0514,827.59-255.56-122.84---369.01-----10,094.19-415.10---------98.69-87.44-154.63---53.68--
Bolt Biotherapeutics Inc11.17m-66.17m24.11m100.00--0.2809--2.16-1.74-1.740.29382.240.0709----111,660.00-42.03-48.32-47.37-54.03-----592.57-2,267.00----0.00--37.48--21.45---6.61--
Unity Biotechnology Inc0.00-27.86m24.26m19.00--1.23-----1.80-1.800.001.170.00----0.00-36.05-47.21-45.11-53.51-------6,395.92----0.00---100.00--10.36---61.28--
Cognition Therapeutics Inc0.00-31.08m24.46m25.00--1.06-----0.9317-0.93170.000.57360.00----0.00-79.36---104.49-------------263.290.00-------20.52------
Iterum Therapeutics PLC0.00-28.34m24.75m14.00---------2.00-2.000.00-0.6580.00----0.00-86.93-118.12-150.76-199.23-------890,554.10----2.06------13.64---32.09--
Promis Neurosciences Inc0.00-12.20m24.76m6.00---------0.6924-0.69240.00-0.12010.00----0.00-839.15-144.28---262.23-------2,271,047.00------------26.85------
Nuo Therapeutics Inc1.03m-2.69m25.01m----41.78--24.31-0.0622-0.06220.02370.01320.73320.9544.06---191.94-116.16-381.40-354.8479.4870.02-261.78-854.531.39-2,383.080.00--442.12-14.990.0095------
Lisata Therapeutics Inc0.00-21.07m25.13m25.00--0.657-----2.56-2.560.004.600.00----0.00-40.16-45.97-43.61-50.47------------0.00------61.57------
SAB Biotherapeutics Inc2.78m-40.32m25.29m57.00--0.5483--9.10-5.69-5.690.36465.000.0571--9.4448,773.51-82.85---102.37-------1,450.32------0.0817---90.63---125.14------
Lipocine Inc4.80m-8.49m25.51m17.00--1.20--5.31-1.60-1.600.90123.970.1794--109.27282,407.70-31.72-39.32-34.05-45.87-----176.80-442.26----0.00---670.16---51.99------
Data as of Sep 19 2024. Currency figures normalised to Tron Pharmaceuticals Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.